Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
49,467,518
-
Shares change
-
+2,562,125
-
Total reported value, excl. options
-
$435,305,054
-
Value change
-
+$17,238,403
-
Put/Call ratio
-
98%
-
Number of buys
-
49
-
Number of sells
-
-39
-
Price
-
$8.80
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q4 2017
118 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q4 2017.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49,467,518 shares
of 116,964,738 outstanding shares and own 42% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7,259,398 shares), FMR LLC (6,684,166 shares), Temasek Holdings (Private) Ltd (6,556,116 shares), BlackRock Inc. (3,198,726 shares), Kohlberg Kravis Roberts & Co. L.P. (3,055,055 shares), STATE STREET CORP (2,104,510 shares), JPMORGAN CHASE & CO (1,924,494 shares), Vanguard Group Inc (1,880,448 shares), CITADEL ADVISORS LLC (1,772,241 shares), and ORBIMED ADVISORS LLC (1,471,500 shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.